How Tamiflu became a global blockbuster

When senior executives from Roche host a briefing for journalists on Monday in Basel, their chosen topic will be unusual for a drug company that focuses on oncology and other hospital-prescribed niche medicines.William Burns, head of pharmaceuticals, will instead discuss Tamiflu, the antiviral drug that has become an unexpected “blockbuster”: with projected sales this year of SFr2bn ($1.9bn, €1.3bn, £1.1bn), it has become Roche’s fourth-biggest selling product. For a drug that was almost stillbo...
From:http://www.ft.com/cms/s/0/cd89a424-9aec-11de-a3a1-00144feabdc0.html